Akso Health Group: Form 20-F for the period ended Mar 31, 2022
Filed with the SEC on Dec 29, 2022 and accepted by EDGAR at Dec 29, 2022, 16:06 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2021-04-01 to 2022-03-31 | $6.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2021-04-01 to 2022-03-31 | $5.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2021-04-01 to 2022-03-31 | $916.2k | us-gaap:GrossProfit |
| Research and development | 12 months2021-04-01 to 2022-03-31 | $421.2k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2021-04-01 to 2022-03-31 | −$15.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2021-04-01 to 2022-03-31 | $131.4k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2021-04-01 to 2022-03-31 | −$16.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2021-04-01 to 2022-03-31 | −$0.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2021-04-01 to 2022-03-31 | −$0.28 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2021-04-01 to 2022-03-31 | 59,612,152 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2021-04-01 to 2022-03-31 | −$8.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2021-04-01 to 2022-03-31 | $4.9k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2022-03-31 | $21.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-03-31 | $50.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-03-31 | $50.7m | us-gaap:Assets |
| Current liabilities | At period end2022-03-31 | $38.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-03-31 | $38.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-03-31 | $12.3m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2022-03-31 | 68,598,050 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001104659-22-130935. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.